RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

Catalysts

About Verastem

Verastem is an oncology company focused on therapies for RAS and MAPK pathway driven cancers, including KRAS mutated recurrent low grade serous ovarian cancer.

What are the underlying business or industry changes driving this perspective?

• The launch of AVMAPKI FAKZYNJA CO-PACK into a high unmet need niche, KRAS mutated recurrent LGSOC as the first treatment specific to this disease, gives Verastem a focused commercial foothold that directly supports future product revenue.
• Broad and deep physician engagement, with 133 prescribers across both academic centers and community practices and around 65% of prescriptions coming from the top 100 organizations, suggests growing brand penetration that can influence prescription volume and top line sales.
• Supportive reimbursement dynamics, including payer coverage above 80%, a roughly balanced commercial and Medicare mix and time to fill around 12 to 14 days, reduce access frictions, which can help prescription conversion and collections on net product revenue.
• Progress in the VS 7375 KRAS G12D program, including clearance of two monotherapy doses without dose limiting toxicities and the move to combination cohorts with cetuximab, extends Verastem's reach across pancreatic, lung and colorectal cancers and is positioned to affect longer term revenue and R&D productivity as data mature.
• Completion of key trial enrollments, such as the RAMP 205 expansion cohort in first line pancreatic cancer and the confirmatory Phase III RAMP 301 trial in recurrent LGSOC with only a modest enrollment increase recommended, tightens the path toward potential registration decisions that could influence future revenue scale and margin structure.
• The combination of an active commercial franchise and a RAS or MAPK focused pipeline, underpinned by a cash position of US$137.7 million and a stated runway into the second half of 2026, gives Verastem room to fund launch activities and clinical development, which directly touches future earnings and the potential to narrow current net losses.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Verastem's revenue will grow by 186.6% annually over the next 3 years.
• Analysts are not forecasting that Verastem will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Verastem's profit margin will increase from -1802.1% to the average US Biotechs industry of 17.0% in 3 years.
• If Verastem's profit margin were to converge on the industry average, you could expect earnings to reach $53.4 million (and earnings per share of $0.65) by about January 2029, up from $-241.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $182.2 million in earnings, and the most bearish expecting $-99.6 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 30.6x on those 2029 earnings, up from -2.0x today. This future PE is greater than the current PE for the US Biotechs industry at 19.7x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.37%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Verastem is currently loss making, with a third quarter 2025 non GAAP adjusted net loss of US$39.4 million and research and development plus SG&A expenses that together significantly exceed the US$11.2 million of net product revenue. If operating costs do not scale efficiently as the business grows, the company could face continued pressure on earnings and net margins.
• The company expects its current cash, cash equivalents and investments of US$137.7 million plus future AVMAPKI FAKZYNJA CO PACK revenue and warrant exercises to fund operations only into the second half of 2026. Any shortfall in product revenue or higher than expected clinical or commercial spend could require additional capital raising that affects existing shareholders and prolongs net losses.
• The commercial launch currently relies on a rare disease niche and a relatively concentrated prescriber base, with about 65% of prescriptions coming from the top 100 organizations and more than half from academic centers. Any slower than expected broadening into community practices or changes in key opinion leader behavior could limit revenue growth and delay any improvement in earnings.
• Future growth plans depend heavily on clinical trial success for RAMP 205, RAMP 301 and the VS 7375 KRAS G12D program. The modest upsizing of the Phase III RAMP 301 trial and the need for additional data and regulatory feedback introduce clinical and regulatory risk that could affect long term revenue potential and keep profit margins under pressure if outcomes or timelines are less favorable than hoped.
• The company benefits today from payer coverage above 80% and time to fill prescriptions of around 12 to 14 days. Any future shifts in reimbursement policies, competitive therapies entering KRAS mutated or related cancer segments, or a change in guideline recommendations such as the pending NCCN review outcomes could affect access and pricing power, with knock on effects for net product revenue and overall margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $16.12 for Verastem based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $14.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $315.0 million, earnings will come to $53.4 million, and it would be trading on a PE ratio of 30.6x, assuming you use a discount rate of 7.4%.
  
• Given the current share price of $6.36, the analyst price target of $16.12 is 60.6% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.